2024
Acute Promyelocytic Leukemia in the Real World: Understanding Outcome Differences and How We Can Improve Them
Bidikian A, Bewersdorf J, Kewan T, Stahl M, Zeidan A. Acute Promyelocytic Leukemia in the Real World: Understanding Outcome Differences and How We Can Improve Them. Cancers 2024, 16: 4092. PMID: 39682277, PMCID: PMC11640703, DOI: 10.3390/cancers16234092.Peer-Reviewed Original ResearchAcute promyelocytic leukemiaAdvent of all-trans retinoic acidEarly mortalityLong-term treatment toxicitiesArsenic trioxidePromyelocytic leukemiaClinical practiceIncidence of acute promyelocytic leukemiaRates of remissionLong-term outcomesTreatment of acute promyelocytic leukemiaLong-term survivalComprehensive patient evaluationResource-limited settingsTreatment toxicityAll-trans retinoic acidDelayed diagnosisPatient demographicsSignificant comorbiditiesTreatment initiationOlder patientsExpert centersClinical trialsTreatment outcomesReal-world settings
2019
Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all
Stahl M, Tallman M. Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all. Leukemia & Lymphoma 2019, 60: 3107-3115. PMID: 31842650, PMCID: PMC7479633, DOI: 10.1080/10428194.2019.1613540.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsArsenic TrioxideDisease-Free SurvivalHemorrhageHumansIncidenceLeukemia, Promyelocytic, AcuteMortalityNeoplasm Recurrence, LocalPractice Guidelines as TopicRandomized Controlled Trials as TopicRemission InductionStandard of CareTime FactorsTretinoinConceptsAcute promyelocytic leukemiaApplication of all-trans retinoic acidArsenic trioxideHigher early death rateHigh-risk acute promyelocytic leukemiaOutcome of high-riskRelapsed APLPromyelocytic leukemiaEarly death rateRelapsed APL patientsTreatment of acute promyelocytic leukemiaAll-trans retinoic acidAPL patientsCare of patientsEarly deathHigh riskPatientsLeukemiaRetinoic acidDeath rateDifferentiation syndrome in acute promyelocytic leukaemia
Stahl M, Tallman M. Differentiation syndrome in acute promyelocytic leukaemia. British Journal Of Haematology 2019, 187: 157-162. PMID: 31410848, DOI: 10.1111/bjh.16151.Peer-Reviewed Original ResearchConceptsAll-trans retinoic acidDifferentiation syndromeAcute promyelocytic leukemia differentiation syndromeArsenic trioxideAcute renal failureTreated with all-trans retinoic acidAcute promyelocytic leukemiaSteroid prophylaxisUnexplained hypotensionPulmonary infiltratesClinical suspicionUnexplained feverPresenting symptomsPericardial effusionProphylaxis strategiesRenal failureImmediate treatmentSevere casesPromyelocytic leukemiaProphylaxisClinical signsRetinoic acidSyndromeSteroidsAPL
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply